United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $524.99, for a total value of $4,987,405.00. Following the sale, the chief executive officer owned 40,513 shares of the company's stock, valued at $21,268,919.87. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
United Therapeutics Stock Performance
Shares of UTHR stock opened at $521.22 on Tuesday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $548.12. The stock's fifty day moving average is $491.17 and its two-hundred day moving average is $469.91. The firm has a market capitalization of $22.85 billion, a P/E ratio of 18.68, a PEG ratio of 1.89 and a beta of 0.84.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.19 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Institutional Trading of United Therapeutics
Hedge funds have recently made changes to their positions in the company. AE Wealth Management LLC lifted its stake in shares of United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company's stock valued at $1,798,000 after purchasing an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC grew its holdings in shares of United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company's stock worth $1,888,000 after purchasing an additional 2,975 shares during the period. Optimize Financial Inc acquired a new stake in shares of United Therapeutics during the 3rd quarter worth about $444,000. Simplify Asset Management Inc. acquired a new stake in shares of United Therapeutics during the 3rd quarter worth about $8,351,000. Finally, Osaic Holdings Inc. raised its holdings in United Therapeutics by 271.0% in the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company's stock valued at $14,027,000 after buying an additional 33,662 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.
Analyst Ratings Changes
Several brokerages recently issued reports on UTHR. HC Wainwright upped their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Royal Bank Of Canada boosted their target price on United Therapeutics from $587.00 to $643.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. Cantor Fitzgerald upped their price target on United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research report on Thursday, March 12th. Bank of America reaffirmed a "neutral" rating on shares of United Therapeutics in a report on Wednesday, February 25th. Finally, UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $549.91.
Read Our Latest Stock Analysis on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
